华北制药股份有限公司 第十一届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华北制药股份有限公司（以下简称"公司"）第十一届董事会第九次 会议于 2023 年 8 月 7 日向全体董事、监事及公司高级管理人员以书面和电 子邮件形式发出会议通知，并于 2023 年 8 月 17 日召开。应参会董事 11 名， 实际参会董事 11 名。会议的召集、召开和表决程序符合《公司法》《公司 章程》及《董事会议事规则》的规定。会议审议并以书面表决方式通过了 以下议案： 一、2023 年半年度报告全文及摘要 具体内容详见公司同日刊登于《中国证券报》《上海证券报》和上海 证券交易所网站（www.sse.com.cn）的《2023 年半年度报告》和《2023 年 半年度报告摘要》。 证券代码：600812 证券简称：华北制药 编号：临 2023-044 财务公司 20%的股权。 具体内容详见公司同日刊登于《上海证券报》《中国证券报》和上海 证券交易所网站（www.sse.com.cn）的《关于向冀中能源集团财务有限责任 ...

3、本次交易尚需提交公司董事会审议批准，与本次关 联交易有关联关系的董事应回避表决。 我们同意该关联交易议案，并同意将该议案提交公司第 十一届董事会第九次会议审议。 独立董事：潘广成、刘骁悍、周德敏、谢纪刚、柴振国 2023 年 8 月 17 日 华北制药股份有限公司关联交易审核委员会 关于对冀中能源集团财务有限责任公司增资涉及关联 交易的审核意见 根据《上海证券交易所股票上市规则》等有关法律法规 规定，公司第十一届董事会关联交易审核委员会对《华北制 药股份有限公司关于向冀中能源集团财务有限责任公司增 资的议案》所涉及的关联交易事项进行了认真审核，认为： 1、本次增加冀中能源集团财务有限责任公司（以下简 称"财务公司"）注册资本，将进一步增强财务公司的资本 实力，优化监管指标，提高抵御风险的能力，保障公司股权 投资安全。 2、根据《企业国有资产交易监督管理办法》规定，本 次增资按财务公司现持股比例增资，不需进行评估，按照财 务公司 2022 年审计报告为依据确定企业资本及股权比例。 各股东均以货币形式按出资比例认缴新增注册资本，同股同 价同权，价格公允，不存在损害公司股东利益的行为。 ...

华北制药股份有限公司独立董事 公司与财务公司的其他股东对财务公司进行同比例增 资，有利于优化财务公司监管指标，提升财务公司抵御风险 的能力，有利于保障公司股权投资安全，交易遵循了公平、 公正、公开的原则，交易合理，符合相关法律、法规及公司 章程的规定。董事会在审议相关议案时，关联董事回避了表 决，符合法律、法规等相关规定，符合公司全体股东的利益。 因此,我们同意公司对财务公司增资事项。 独立董事：潘广成、刘骁悍、周德敏、谢纪刚、柴振国 2023 年 8 月 17 日 关于向冀中能源集团财务有限责任公司增资涉及关联 交易的独立意见 我们作为华北制药股份有限公司（以下简称"公司"） 的独立董事，根据《公司法》、中国证监会《上市公司独立 董事规则》、《上海证券交易所股票上市规则》及《公司章程》 和《公司独立董事工作制度》等相关规定，基于独立判断立 场，对向冀中能源集团财务有限责任公司（下称"财务公司"） 增资事项发表独立意见如下： ...

证券代码：600812 证券简称：华北制药 编号：临 2023-037 1 华北制药股份有限公司 关于参加2023年河北辖区上市公司投资者网上集体接待日 活动暨2022年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●召开时间：2023年5月30日(星期二) 下午15:00-17:00 ●召开地点："全景路演"（http://rs.p5w.net/） ●召开方式："全景路演"网络互动。 ●投资者可于2023年5月29日（星期一）16:00前将需要了解和关注的问题通过电子邮件 的形式发送至公司邮箱 ncpcdshbgs@163.com。公司将在本次说明会上对投资者普遍关注的 问题进行回答。 华北制药股份有限公司（以下简称"公司"）已于2023年4月22日在上 海证券交易所网站（www.sse.com.cn）披露了公司《2022年年度报告》。为 便于广大投资者更全面深入地了解公司2022年年度经营成果、财务状况等， 公司计划于2023年5月30日（星期二）下午15:00-17:00参加由河北 ...

证券代码：600812 证券简称：华北制药 编号：临 2023-037 华北制药股份有限公司 关于参加2023年河北辖区上市公司投资者网上集体接待日 活动暨2022年年度业绩说明会的公告 华北制药股份有限公司（以下简称"公司"）已于2023年4月22日在上 海证券交易所网站（www.sse.com.cn）披露了公司《2022年年度报告》。为 便于广大投资者更全面深入地了解公司2022年年度经营成果、财务状况等， 公司计划于2023年5月30日（星期二）下午15:00-17:00参加由河北证监局、 河北省上市公司协会与深圳市全景网络有限公司联合举办的2023年河北辖 区上市公司投资者网上集体接待日活动暨2022年年度业绩说明会（以下简 称"本次活动"），就投资者普遍关心的问题进行交流。 一、本次活动类型 1 ●召开时间：2023年5月30日(星期二) 下午15:00-17:00 ●召开地点："全景路演"（http://rs.p5w.net/） ●召开方式："全景路演"网络互动。 本次活动以网络互动形式召开。公司将就2022年年度业绩、公司治理、 发展战略、经营状况、融资计划、股权激励和可持续发展等情况与投资者 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥2,660,096,706.22, representing a year-on-year increase of 4.59%[6] - Net profit attributable to shareholders of the listed company decreased by 60.38% to ¥5,420,341.81 compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,086,080.64, a decrease of 169.54% year-on-year[6] - Basic and diluted earnings per share were both ¥0.003, down 62.50% from the previous year[6] - The company reported a net loss of CNY 601,083,049.19 for Q1 2023, slightly improved from a net loss of CNY 606,503,391.00 in Q1 2022[27] - The net profit for Q1 2023 was CNY 6,546,123.55, a decrease of 66.0% compared to CNY 19,196,750.52 in Q1 2022[31] - Operating profit for Q1 2023 was CNY 36,450,940.95, down 11.8% from CNY 41,184,658.02 in the same period last year[31] - The total operating profit for Q1 2023 was CNY 18,931,965.78, compared to CNY 68,174,477.62 in Q1 2022, reflecting a significant decrease[46] - The net profit for Q1 2023 was CNY 21,339,797.92, down from CNY 64,533,832.18 in the same period last year[46] Cash Flow - The net cash flow from operating activities increased significantly by 404.11% to ¥187,858,742.38, mainly due to an increase in cash collections[6] - Cash flow from operating activities netted CNY 187,858,742.38 in Q1 2023, a significant increase from CNY 37,265,495.04 in Q1 2022[36] - The total amount of cash received from operating activities was CNY 2,055,067,700.88, while cash paid for goods and services was CNY 825,897,402.46 in Q1 2023[36] - The net cash flow from financing activities was CNY 308,525,208.29, a significant improvement from a negative cash flow of CNY -667,914,386.06 in the previous year[38] - The net cash flow from financing activities improved to CNY 106,704,458.19 in Q1 2023, compared to a negative CNY 961,604,887.43 in Q1 2022[49] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥21,819,916,060.13, an increase of 2.82% from the end of the previous year[9] - Total assets reached CNY 21,819,916,060.13 as of March 31, 2023, compared to CNY 21,221,017,906.40 at the end of 2022, marking a growth of 2.8%[25] - Total liabilities increased to CNY 15,585,239,520.50 in Q1 2023 from CNY 14,992,641,818.84 in Q4 2022, reflecting a rise of 3.9%[26] - The total liabilities amounted to CNY 11,991,449,739.57, compared to CNY 11,693,543,754.40 in the previous year, indicating a rise in financial obligations[44] Equity - The equity attributable to shareholders of the listed company was ¥5,305,299,999.21, a slight increase of 0.10% compared to the end of the previous year[9] - The total equity attributable to shareholders was CNY 5,305,299,999.21 as of March 31, 2023, compared to CNY 5,300,125,328.88 at the end of 2022, showing a marginal increase of 0.1%[27] - The total equity increased to CNY 6,790,179,729.59 from CNY 6,768,839,931.67, reflecting a growth in shareholder value[44] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 2,624,501,680.17, up from CNY 2,498,274,235.59 in Q1 2022, reflecting a year-over-year increase of 5.0%[27] - Research and development expenses increased significantly to CNY 66,514,021.08 in Q1 2023, up 99.5% from CNY 33,337,722.55 in Q1 2022[31] - Research and development expenses for Q1 2023 were CNY 13,324,018.64, significantly higher than CNY 4,374,035.32 in Q1 2022, indicating increased investment in innovation[44] - The company incurred financial expenses of CNY 131,734,667.63 in Q1 2023, down from CNY 142,638,164.40 in Q1 2022, a reduction of 7.0%[31] - The company reported a decrease in financial expenses to CNY 85,675,989.61 from CNY 109,874,458.68, indicating better cost management[44] Inventory and Receivables - Accounts receivable increased to CNY 2,397,251,350.19 in Q1 2023 from CNY 2,231,066,181.09 in Q4 2022, indicating a rise of 7.5%[22] - Inventory as of March 31, 2023, was CNY 2,565,609,361.14, slightly up from CNY 2,523,301,463.29 at the end of 2022, showing an increase of 1.7%[22] - The company's inventory increased to CNY 1,233,877,392.97 from CNY 1,136,776,702.39, reflecting a growth of approximately 8.5% year-over-year[38]

Financial Performance - In 2022, the company reported a net loss of approximately ¥678.78 million, with a net loss attributable to shareholders of approximately ¥689.23 million[5]. - The company's parent entity achieved a net profit of approximately ¥28.12 million for the year[5]. - The undistributed profits at the end of 2022 amounted to approximately ¥739.78 million after accounting for the legal surplus reserve and previous year dividends[5]. - The company plans not to distribute profits for 2022, nor to increase capital reserves through stock conversion, to ensure sustainable development and risk resilience[5]. - The company achieved an operating revenue of CNY 10.50 billion in 2022, a year-on-year increase of 1.11% compared to CNY 10.38 billion in 2021[22]. - The net profit attributable to shareholders was CNY -689.23 million, a significant decrease of 3,780.33% from CNY 18.73 million in 2021[22]. - The company recorded a net cash flow from operating activities of CNY 1.00 billion, down 4.37% from CNY 1.05 billion in 2021[22]. - The weighted average return on equity decreased to -12.11% in 2022, down 12.42 percentage points from 0.31% in 2021[23]. - The company reported a total asset value of CNY 21.22 billion at the end of 2022, a decrease of 14.88% from CNY 24.93 billion at the end of 2021[22]. - The total profit decreased to -565 million RMB, a decline of 518.87% compared to the previous year[60]. Operational Challenges - The company faced significant challenges, including a provision for bad debts of CNY 727.39 million related to relocation and suspension losses, impacting the net profit[32]. - The company generated CNY 2.54 billion in revenue in Q1 2022, with a net profit of CNY 13.68 million, but reported a net loss of CNY 727.17 million in Q4 2022[27]. - The company has not engaged in non-operational fund occupation by controlling shareholders or related parties[7]. - There were no significant risks that materially affected the company's operations during the reporting period[9]. Research and Development - The company increased its R&D investment to 609 million yuan, achieving an investment intensity of 5.80%[34]. - The company applied for 52 patents in 2022, including 33 invention patents, and was granted 45 patents[34]. - The company established three provincial-level research platforms, enhancing its R&D capabilities[34]. - The company is actively pursuing strategic collaborations with key universities and research institutions to accelerate product development[34]. - The company has established a comprehensive R&D system, including 4 national innovation platforms and 11 provincial innovation platforms, enhancing its research capabilities[105]. - The company is currently developing several new products, including a new anticoagulant drug in clinical trial phase and a rabies virus antibody product that received its registration certificate in January 2022[106]. Market Expansion and Sales Strategy - The company successfully expanded its international market, achieving overseas sales of CNY 1.59 billion in 2022[33]. - The company implemented a new marketing strategy, including an internet marketing plan, to enhance its sales capabilities and stabilize its revenue base[33]. - The company is exploring online drug sales, gradually increasing the number of varieties and expanding specialized treatment categories[46]. - The company is focusing on developing new treatment areas such as cardiovascular, anti-tumor, kidney disease, and diabetes products[59]. - The company plans to continue expanding its market presence and product diversity in response to changing market conditions[66]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[94]. Environmental Responsibility - The company invested 24,000,000 CNY in environmental protection during the reporting period[186]. - The company has established a comprehensive environmental management system and has passed the ISO14001 certification[187]. - The company operates 14 key pollutant discharge units across 19 production sites, demonstrating its commitment to environmental responsibility[188]. - The company has implemented a performance evaluation system for senior management, linking compensation to company performance[181]. - The company’s wastewater discharge is continuously monitored and complies with the standards set by the downstream sewage treatment plant[189]. Corporate Governance - The company has maintained a policy of independence from its controlling shareholders, ensuring no significant impact from related party transactions[148]. - The company has established specialized committees under the board, including an audit committee and a strategic committee, to enhance governance[165]. - The company has a structured process for nominating and compensating its directors and senior management, ensuring transparency and accountability[159]. - The company has actively participated in board and shareholder meetings, with directors attending all required sessions[163]. - The company has undergone changes in its board of directors, with several members being elected or resigning due to age or work reasons[160]. Future Outlook - The company is focused on cost reduction, efficiency improvement, and risk control as part of its operational strategy for 2023[135]. - The company plans to enhance its governance structure and improve operational efficiency in 2023[136]. - The company aims to achieve operating revenue of 11 billion yuan and a total profit of 120 million yuan in 2023[135]. - The company provided guidance for the next quarter, expecting revenue to be between $1.6 billion and $1.7 billion, which reflects a growth rate of approximately 10%[94]. - Future outlook remains positive, with expectations of improved financial performance driven by strategic initiatives[153].

Financial Performance - The company's operating revenue for Q3 2022 was approximately ¥2.59 billion, a decrease of 0.35% compared to the same period last year[7]. - Net profit attributable to shareholders was approximately ¥5.56 million, down 66.85% year-on-year, while year-to-date net profit increased by 113.39% to approximately ¥37.94 million[7][13]. - Basic and diluted earnings per share were both ¥0.003, reflecting a 70% decrease compared to the previous year[9]. - Total operating revenue for the first three quarters of 2022 was CNY 7,873,258,693.27, a decrease of 3.82% compared to CNY 8,186,782,145.76 in the same period of 2021[32]. - Net profit attributable to shareholders of the parent company for Q3 2022 was CNY 37,935,682.09, an increase of 113.57% from CNY 17,777,880.20 in Q3 2021[36]. - The company reported a total comprehensive income of CNY 62,428,111.51 for Q3 2022, compared to CNY 23,390,347.48 in Q3 2021, indicating a significant increase[38]. - The company’s basic and diluted earnings per share for Q3 2022 were both CNY 0.022, doubling from CNY 0.011 in Q3 2021[38]. - The net profit for the third quarter of 2022 was approximately ¥331.97 million, compared to ¥140.17 million in the same quarter of 2021, indicating a significant increase of 136.5%[54]. Cash Flow - The net cash flow from operating activities for the year-to-date period was approximately ¥533 million, a decrease of 17.04% compared to the same period last year[9]. - The company reported a decrease in cash flow from operating activities, impacting liquidity and operational flexibility[23]. - Cash inflow from operating activities totaled CNY 7,580,741,283.11, an increase from CNY 6,942,108,928.76 in the previous period, representing a growth of approximately 9.2%[42]. - Cash outflow from operating activities was CNY 7,047,722,200.67, compared to CNY 6,299,646,223.30 in the prior period, indicating an increase of about 11.9%[42]. - Net cash flow from operating activities decreased to CNY 533,019,082.44 from CNY 642,462,705.46, reflecting a decline of approximately 17%[42]. - Cash inflow from financing activities amounted to CNY 8,684,036,714.11, up from CNY 8,521,717,205.00, marking an increase of about 1.9%[44]. - Cash outflow from financing activities rose significantly to CNY 11,996,243,011.53 from CNY 7,462,991,263.62, representing an increase of approximately 60.5%[44]. - The net cash flow from financing activities showed a negative balance of CNY -3,312,206,297.42, compared to a positive CNY 1,058,725,941.38 in the previous period[44]. - Cash flow from operating activities generated a net amount of approximately ¥399.07 million in 2022, down from ¥489.90 million in 2021, a decrease of 18.5%[56]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥23.16 billion, a decrease of 7.11% year-on-year[9]. - The company's equity attributable to shareholders was approximately ¥6.03 billion, down 0.88% from the previous year[9]. - The company's total assets amounted to CNY 23,156,852,612.93, a decrease from CNY 24,929,934,674.93 at the end of 2021[23]. - The company's current assets decreased to CNY 10,948,563,970.74 from CNY 12,712,195,682.24 year-over-year[27]. - The company's total liabilities decreased to CNY 16,193,809,118.95 from CNY 17,912,703,964.04[30]. - The total liabilities and shareholders' equity as of the end of the reporting period was CNY 23,156,852,612.93, down from CNY 24,929,934,674.93[32]. - The total liabilities decreased to approximately ¥11.63 billion in 2022 from ¥13.44 billion in 2021, a reduction of 13.5%[50]. - The total equity increased to approximately ¥7.07 billion in 2022 from ¥6.84 billion in 2021, showing a growth of 3.4%[50]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 92,202[14]. - The largest shareholder, Jizhong Energy Co., Ltd., held 24.08% of the shares, while Huabei Pharmaceutical Group held 19.90%[14]. Accounting Changes - The company has implemented changes in accounting practices affecting the presentation of transportation costs in the income statement, which do not impact net profit or net assets[9]. - The company has adopted new accounting standards starting from 2022, which may affect the financial statements[58].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15% compared to the same period last year[22]. - The net profit attributable to shareholders for the first half of 2022 was RMB 200 million, an increase of 10% year-on-year[22]. - The company's operating revenue for the reporting period was approximately ¥5.28 billion, a decrease of 5.45% compared to the previous year[25]. - Net profit attributable to shareholders was approximately ¥32.38 million, showing a significant increase of 3,121.28% year-on-year[25]. - The net profit after deducting non-recurring gains and losses was approximately ¥13.79 million, compared to a loss of ¥30.01 million in the same period last year[25]. - The net cash flow from operating activities was approximately ¥230.93 million, down by 5.08% from the previous year[25]. - Basic earnings per share increased to ¥0.019, a rise of 1,800.00% compared to the same period last year[25]. - The total profit for the period was CNY 0.97 billion, with a net cash flow from operating activities of CNY 230.93 million, down 5.08% year-on-year[51]. - Research and development expenses increased by 61.59% to CNY 104.41 million, reflecting the company's commitment to enhancing innovation capabilities[51]. - The company reported a decrease in undistributed profits by 37.44% year-on-year, amounting to CNY 117.92 million[58]. Market Expansion and Product Development - The company has expanded its user base by 20% in the first half of 2022, reaching a total of 1.5 million active users[22]. - The company plans to launch three new products in the second half of 2022, focusing on innovative drug formulations[22]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 30% increase in market share by the end of 2023[22]. - The company is focusing on the development of biopharmaceuticals and strengthening its position in chemical pharmaceuticals, while also expanding into health consumer products and veterinary medicine[32]. - The company focuses on high-value and high-growth projects in new therapeutic areas such as cardiovascular, anti-tumor, kidney disease, and diabetes[46]. Research and Development - The company has invested RMB 100 million in research and development for new technologies in the first half of 2022, which is a 25% increase from the previous year[22]. - The company has established 3 national-level R&D platforms and 8 provincial-level R&D platforms, enhancing its research capabilities[47]. - The company has received 5 national invention awards and 21 scientific and technological progress awards, highlighting its strong R&D capabilities[40]. - The company successfully registered 8 patents during the reporting period, with 13 patents granted, including 6 invention patents[47]. Environmental Compliance and Management - The company has established a comprehensive environmental management system, ensuring that all pollution prevention facilities operate normally and comply with emission standards[183]. - The company has implemented a comprehensive pollution prevention and control strategy, ensuring that pollution control facilities operate in sync with production equipment[87]. - The company has established emergency response plans for environmental incidents, ensuring preparedness for potential environmental risks[147]. - The company operates under the "Comprehensive Discharge Standard for Atmospheric Pollutants" and other relevant environmental standards[152]. - The company has maintained compliance with noise emission standards as per the "Industrial Enterprise Boundary Environmental Noise Emission Standard"[146]. Social Responsibility and Community Engagement - The company aims to increase the annual income of policy beneficiaries by an estimated RMB 500-1,000, with collective village income expected to exceed RMB 50,000[188]. - The company has expanded its green planting project in Yanjiakou Village, increasing the planting area from 11 mu to 26 mu, benefiting more households and creating nearly 50 short-term job opportunities[191]. - The company has received provincial recognition for its outstanding performance in poverty alleviation efforts in Yanjiakou and Yaogou Villages[191]. - The company has deployed 6 team members to support rural revitalization efforts in Zhangjiakou City, focusing on agriculture and tourism projects[192]. - The overall relocation project in the village has been completed, with all villagers moving into 120 new homes[193].

Financial Performance - The company's operating revenue for 2021 was approximately ¥10.38 billion, a decrease of 9.64% compared to ¥11.49 billion in 2020[27]. - The net profit attributable to shareholders was ¥18.73 million, down 80.76% from ¥97.32 million in the previous year[27]. - The net cash flow from operating activities increased by 39.63% to ¥1.05 billion, compared to ¥752.15 million in 2020[27]. - The total assets at the end of 2021 were approximately ¥24.93 billion, reflecting a 4.17% increase from ¥23.93 billion in 2020[27]. - The basic earnings per share for 2021 were ¥0.011, a decline of 81.67% from ¥0.060 in 2020[28]. - The company reported a net loss of ¥49.20 million after deducting non-recurring gains and losses, compared to a loss of ¥61.91 million in 2020[27]. - The weighted average return on equity decreased to 0.31% from 1.70% in the previous year[28]. - Total revenue for the company was approximately ¥10.30 billion, a decrease of 9.85% compared to the previous year[64]. - The gross profit margin decreased by 0.25 percentage points to 35.37%[64]. - Total profit amounted to CNY 135 million, reflecting a year-on-year decline of 27.73%[60]. Dividend and Retained Earnings - The company plans to distribute a cash dividend of RMB 0.6 per 10 shares, totaling RMB 102,943,822.2, which represents 549.69% of the net profit attributable to shareholders for the year[6]. - As of December 31, 2021, the company has retained earnings of RMB 714,464,297.92 to be carried forward for future distribution[6]. - The company has not proposed any capital reserve transfer to increase share capital for the current period[6]. Internal Control and Audit - The company reported no significant risks that could materially affect its operations during the reporting period[8]. - The company has identified one major internal control deficiency in its internal control evaluation report for 2021[11]. - The company has received a standard unqualified audit opinion from Zhongtian Yun Accounting Firm for its financial statements[5]. - The company’s financial report has been confirmed for its authenticity, accuracy, and completeness by its board of directors and senior management[4]. - The company has not faced any violations in decision-making procedures regarding external guarantees[8]. Research and Development - The company applied for 41 patents, including 25 invention patents, and was awarded first, second, and third prizes in provincial science and technology progress[36]. - The company has made significant progress in the consistency evaluation of generic drugs, with 11 varieties and 21 specifications passing the evaluation[36]. - The company is focusing on the development of specialty and innovative raw materials to increase the proportion of high-value-added products[45]. - The company is actively pursuing research and development initiatives to enhance its pipeline of injectable antibiotics, aiming for a 15% increase in R&D investment over the next fiscal year[97]. - The company’s R&D investment amounted to 505 million RMB, representing 4.86% of operating revenue, which is in line with the industry average[131]. Market and Product Development - The company is recognized as one of the largest chemical pharmaceutical enterprises in China, with total assets nearing 25 billion yuan and annual sales exceeding 10 billion yuan[42]. - The company is focusing on integrating raw material and formulation development to enhance competitiveness in the pharmaceutical market[90]. - The company is exploring potential mergers and acquisitions to strengthen its position in the pharmaceutical market and expand its product portfolio[97]. - The company aims to enhance its international competitiveness through a unified export platform for formulations[58]. - The company is committed to optimizing its resource allocation and organizational support to align with its strategic goals of marketization, capitalization, and internationalization[152]. Governance and Management - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 10.6479 million yuan[186]. - The company has implemented a performance evaluation system for directors and senior management, which influences their remuneration based on performance results[186]. - The company appointed new independent directors and a chairman through shareholder meetings, indicating a change in governance structure[186]. - The company has a total of 8 key management personnel changes during the reporting period, indicating active management restructuring[186]. - The company’s governance structure has been reinforced with the election of new board members, ensuring alignment with corporate strategy[186]. Operational Efficiency and Cost Management - The company's operating costs decreased by 9.20% to CNY 6.70 billion[60]. - The overall operating cost decreased by 9.50% year-over-year, indicating improved cost management[115]. - The company plans to reduce operational costs by 10% through efficiency improvements in the supply chain[177]. - The company reported a significant reduction in procurement costs for logistics and other trade by 42.63% year-on-year, primarily due to decreased logistics business volume[72]. Future Outlook - The company aims to achieve a revenue target of 38 billion CNY in 2022, focusing on market-oriented and capital-driven strategies[153]. - The management has provided guidance for the next quarter, expecting a revenue growth of approximately 10%[173]. - The company is considering strategic acquisitions to enhance its market position, with a budget of 300 million allocated for potential deals[177]. - The company anticipates a 10% growth in revenue for the upcoming fiscal year, driven by new product launches and market expansion strategies[97].